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Integrating phosphoproteomics into the 
clinical management of prostate cancer
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Abstract 
Phosphoproteomic analysis of tumor samples has the potential to uncover significant insights into kinase signaling 
networks present in late stage prostate cancer that are complementary to genomic and transcriptomic approaches. 
Phosphoproteomics could potentially aid drug development in clinical trial design as well as provide utility for 
oncologists in the personalized therapeutic management of individual cancers through identifying novel biomarkers 
and druggable targets. Rapid advancement of targeted mass spectrometry platforms is underway to integrate phos-
phoproteomic technology with genomic assays to soon translate this information into the cancer clinic.
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Current clinical state of prostate cancer
In 2016, the American Cancer Society estimates 181,890 
new cases of prostate cancer in men in the United States, 
which ranks as the highest among cancers in men and 
second only to lung cancer in estimated deaths at 26,120 
[1]. In advanced stages of the disease, androgen depriva-
tion therapy (ADT) is the primary approach to reduce 
tumor burden. This hormonal therapy is effective initially, 
as assessed by the decline in prostate specific antigen 
(PSA) levels. However, this response is not durable and 
almost always results in relapse, termed castration resist-
ant prostate cancer (CRPC). CRPC is often accompanied 
by the development of radiographically visible metas-
tases. Metastatic castration-resistant prostate cancer 
(mCRPC) represents the lethal form of the disease where 
prognosis is poor with a median survival time of less than 
two years [2]. The best available treatment options for 
mCRPC patients, including second-generation antian-
drogens and taxane-based chemotherapies, modestly 
improve survival by a few months [2–4]. This highlights 
the urgent need to identify more impactful agents and 
a patient-specific approach tailored to treat each tumor 
uniquely.
Unlike in early stage disease, where the development 
of the PSA test to screen patients for prostate cancer has 
both raised awareness and improved survival [1], find-
ing useful biomarkers for patient stratification or therapy 
in mCRPC remains a clinical challenge [3, 4]. One issue 
is that prostate cancer has relatively low mutation rates 
when compared to other types of cancer [5, 6]. Nonethe-
less, several fascinating papers that analyzed the genomic 
and transcriptomic landscape of primary prostate cancer 
and mCRPC identified numerous point mutations, trans-
locations, and amplifications [5–11]. While several of 
these mutations may be deemed actionable, no effective 
treatments have yet been developed that target a major-
ity of these mutations, with the exception of DNA repair 
and androgen receptor (AR) mutations. Indeed, a recent 
clinical trial illustrated that patients with BRCA2 or ATM 
functional loss (deletion or mutation) responded favorably 
to olaparib whereas patients without these mutations did 
not [12]. Another breakthrough paper found that patients 
who exhibited resistance to abiraterone acetate or enzalu-
tamide harbor the AR-V7 splice variant in their prostate 
circulating tumor cells (CTCs) [13]. These selected exam-
ples of novel biomarkers will no doubt improve the treat-
ment landscape for patients with mCRPC. However, due 
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to modest improvements in overall survival, it is impor-
tant to consider other strategies such as proteomics and/
or phosphoproteomics to illuminate our understanding 
of the pathways that drive this disease. These methods 
would complement nicely with existing genomic and tran-
scriptomic information to prioritize the key drivers and 
corresponding treatments in mCRPC.
Integrating clinical omics
Since the turn of the century, genomic technologies have 
matured to a point where practicality is no longer in 
question. Advances in sequencing technologies have both 
reduced cost and increased effectiveness of obtaining 
genomic and transcriptomic data. In parallel, advances 
in the biomedical field has benefited from the increase 
in knowledge from sequencing. Projects such as The 
Cancer Genome Atlas (TCGA) and International Can-
cer Genome Consortium (ICGC) have provided a rich 
resource of genomic information for scientists to apply 
to their research. As a result, clinical practice has gradu-
ally transformed to incorporate genomics in diagnosis, 
patient stratification, and treatment selection [14]. Con-
versely, clinical proteomic and phosphoproteomic plat-
forms have taken longer to develop, owing to the greater 
complexity and difficulty involved with analyzing pro-
teins or phosphoproteins in very small tissue amounts 
(i.e., biopsy).
Even with these current limitations proteomics and 
phosphoproteomics have provided a wealth of informa-
tion from clinically relevant cancer tissues. Work by us 
and the National Cancer Institute’s Clinical Proteomic 
Tumor Analysis Consortium (CPTAC; previously the 
Clinical Proteomic Technology Assessment for Cancer) 
have published some groundbreaking papers in colo-
rectal, ovarian, breast, and prostate cancer characteriz-
ing the genomic, proteomic, and/or phosphoproteomic 
landscapes in these diseases [15–19]. These studies have 
provided clues into the signaling networks related to each 
cancer type through incorporation of novel proteomic 
and phosphoproteomic data. Importantly, these studies 
have opened up new opportunities to develop and test 
computational strategies that will integrate proteomic or 
phosphoproteomic information with existing genomic 
data. Hence, a significant next step will be to extract 
clinically actionable information from these integrated 
approaches.
In prostate cancer, previous work by our group on the 
tyrosine phosphoproteome in mCRPC patients identified 
several activated tyrosine kinases and observed inter-
patient heterogeneity but similarity among metastatic 
sites within the same patient [19]. This may imply that 
evaluation of the phosphoproteome of a singly biopsy 
could reveal the crucial activated signaling pathways to 
inform treatment decisions or aid in the development 
of prognostic or predictive biomarkers during response 
or relapse to current therapies in mCRPC patients. The 
main issue, though, was devising a method to portray 
which kinases or pathways to prioritize from within the 
complex phosphoproteomic data. Our recent publica-
tion in Cell [16] attempted to resolve this issue through a 
defined, systematic approach that integrated several omic 
datasets from mCRPC patient tumor samples using a 
novel computational pipeline [20]. Our analysis revealed 
that inclusion of the phosphoproteomic data provided 
more functional pathway information after integration 
with genomics and transcriptomics versus the integra-
tion of only genomics and transcriptomics. Certain path-
ways (e.g., AKT/mTOR/MAPK, nuclear receptor, and cell 
cycle signaling) were found to be significantly enriched in 
mCRPC when the phosphoproteomic data was included 
but only marginally enriched when excluded [16]. To 
easily visualize specific patients’ signaling networks in 
the context of canonical cancer hallmark pathways, we 
created the phosphorylation-based cancer hallmarks 
using integrated personalized signatures (pCHIPS). It is 
important to note that every patient we evaluated had 
enrichment of at least four cancer hallmarks making pri-
oritization of kinase pathways still very challenging.
To overcome this, we incorporated the pathway infor-
mation to procure a set of targetable kinases predicted 
to have maximal effect on these cancer hallmarks. These 
patient-specific kinase hierarchies make it possible to 
stratify mCRPC patients according to these hierarchies 
using targeted kinase inhibitors, in combination with 
other agents, for maximum therapeutic potential [16]. 
Two major findings came from this approach: (1) Not 
every patient would be predicted to respond to the same 
kinase inhibitor (even though the same cancer hallmark 
pathway may be enriched) and (2) Involvement of the cell 
cycle pathway is very prominent in a majority of these 
patient samples suggesting that CDK4/6 kinase inhibitors 
may be highly efficacious clinically, especially in combi-
nation with other targeted agents. It should be mentioned 
that our phosphoproteomic data could also be influenced 
by activation (or repression) of phosphatases. Our focus 
was on activated kinases, but we cannot rule out the 
notion that hyperphosphorylation of these kinases (or 
their substrates) may be regulated by phosphatase activ-
ity. In addition to kinase inhibitors, our phosphoprot-
eomic information could also help inform the selection 
of phosphatase inhibitors, which may provide a greater 
pleiotropic effect when compared to single agent kinase 
inhibitors, though none are currently FDA-approved 
[21]. While these results are exciting, further experimen-
tal validation in vitro and in vivo is needed to confirm the 
implicated pathways.
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Clinical phosphoproteomics: opportunities 
and challenges
Kinase inhibitors have long been important players in the 
area of targeted therapies against cancer. However, clini-
cal trials using kinase inhibitors where randomization 
is preferred over biomarker stratification have reported 
mixed results, with a majority of these studies not dem-
onstrating any clinical benefit, especially in prostate can-
cer [22, 23]. An explanation for some of these clinical 
trial failures may result from primary or acquired drug 
resistance mechanisms. Many resistance pathways have 
been discovered during the administration of therapies 
targeting driver kinase mutations in several cancers and 
hence can reduce the durability of these targeted agents 
[24, 25]. For example, it has been observed that EGFR 
pathway activity is responsible for the continued growth 
and survival of BRAF (V600E) colon cancers resistant 
to vemurafenib, an observation not observed in BRAF 
(V600E) melanomas [26]. It is our view that future clini-
cal trial successes will hinge on properly stratifying 
patients according to predicted drug response by utiliz-
ing biomarkers that accurately reflect the tumor’s biology. 
The incorporation of phosphoproteomics with genom-
ics and transcriptomics could help characterize how a 
patient’s tumor responds to treatment as well as tease 
out any future mechanisms of resistance providing these 
necessary biomarkers. In that light, a soon to be initiated 
phase II clinical trial in prostate cancer (NCT03012321) 
will utilize genomics to pre-select patients with DNA 
repair mutations followed by randomization to evalu-
ate the efficacy of olaparib alone or in combination with 
an androgen synthesis inhibitor, abiraterone acetate. As 
we move forward, it would be expected that biomarker-
driven clinical trials will be the norm rather than the 
exception, providing clinicians with a method for strati-
fying late stage disease as well as selecting the appropri-
ate therapy for each stratum (Fig. 1).
Phosphoproteomic technologies have made signifi-
cant progress in the past decade with several platforms 
available: antibody-based assays (e.g., reverse phase pro-
tein arrays) and MS-based assays. MS-based assays are 
further delineated into discovery/global and targeted 
approaches [27]. Antibody-based approaches require 
low sample amounts, which makes them practical in the 
clinical setting where biopsies are typically performed. 
Furthermore, these assays do not require special instru-
mentation, easing their adoption into clinical laborato-
ries. However, this approach is reliant on the availability 
of quality, specific antibodies, which can be more difficult 
when evaluating phosphorylation. MS-based approaches 
can bypass this limitation and perform multiplexed 
analysis of many proteins or phosphoproteins at once 
[27]. MS-based assays, specifically the targeted platform, 
carry great potential for future clinical utility especially 
in the space of diagnostic and predictive biomarker 
development. The global MS platform allows for relative 
quantitative comparisons of an unknown list of phos-
phopeptides between samples. The technique involves 
extracting proteins from the sample and digesting with 
a protease (usually trypsin plus Lys-C) into peptides and 
phosphopeptides [28]. Due to the relatively lower abun-
dance of phosphoproteins, the phosphopeptides require 
enrichment from the complex mixture [29]. This can be 
done using immobilized metal affinity chromatography 
(IMAC) [30] such as TiO2 or antibodies (for phospho-
tyrosine enrichment) [31]. The enriched sample is then 
separated by liquid chromatography and detected via 
tandem MS. Detected peptides and phosphopeptides 
can be analyzed using software programs such as Max-
Quant [32] or Skyline [33]. However, global MS is limited 
by its reproducibility due to the biased nature of the MS 
method [34]. Systemic bias in data collection arises from 
the complex digests and experimental design [34, 35]. 
Furthermore, phosphopeptides of higher abundance are 
sampled more frequently and precisely while phospho-
peptides of lower abundance may be missed, creating a 
missing values problem [34, 35]. Efforts are ongoing in 
standardizing normalization strategies and data impu-
tation methods to address these challenges both within 
experiments and across experiments [35, 36]. Targeted 
MS can bypass these limitations by measuring specifi-
cally annotated peptides that are constituent to a pro-
tein of interest. By using isotope-labeled standards and 
acquiring MS data specifically for the peptides of interest, 
targeted MS can precisely and reproducibly quantitate 
that protein in the sample by using previously mentioned 
programs such as Skyline [34]. Adoption of targeted MS 
to examine biomedical problems is growing and best 
practices are emerging to begin to standardize the field 
[37]. Crucial to this effort, the CPTAC network of labora-
tories demonstrated high reproducibility of this approach 
within and between laboratories as well as across instru-
ments in measuring protein concentrations in plasma 
[38].
As phosphoproteomic technologies mature we fore-
see a paradigm shift. Clinicians will order tests that 
evaluate pathway activity as well as mutational status 
and will apply these results in real-time in the clinic. 
Until that day arrives, more work is still needed in the 
field of phosphoproteomics that improve upon some 
of the same sets of challenges that early work in the 
genomics field faced nearly 15 years ago. Phosphoprot-
eomic MS platforms require greater amounts of sample 
as well as greater upfront investment on infrastructure 
in terms of equipment and operator expertise [27]. 
Furthermore, the assay workflow is lengthy, limiting 
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reproducibility as well as practicality. We anticipate that 
many of these issues will be solved with continual tech-
nological advancement. Reducing the sample require-
ment amount will make the platform more practical 
for biopsy-based tests in the clinic. Indeed, a recent 
landmark paper demonstrated reproducible detection 
and quantification of over 2000 proteins from 18 clini-
cal biopsy samples by utilizing novel pressure cycling 
technology and sequential window acquisition of all 
theoretical fragment ion mass spectra (SWATH-MS) 
[39]. While exciting, further investigation is neces-
sary to determine if phosphopeptides can be detected 
in the same manner due to the relatively lower abun-
dance of phosphopeptides when compared to total pep-
tides. Efforts to simplify the workflow [40] will reduce 
the turn-around time between sample collection and 
results, enabling clinicians to more quickly evaluate and 
determine the next step in disease management.
Fig. 1 Conceptual diagram of the integration of phosphoproteomics into prostate cancer clinical management. a A biopsy of the tumor is taken 
from a metastatic castration-resistant prostate cancer (mCRPC) patient. b The biopsy specimen is processed to generate its omics data. c The omics 
data is integrated to produce a personalized pathway signature. d Drug targets are identified from this signature. e Available drugs are assessed for 
each drug target. f The drug or combinations of drugs that block the target are selected for treatment in addition to standard of care as an arm in a 
clinical trial 
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Conclusions
While MS-based targeted phosphoproteomics is in pre-
clinical stages of research and development, we believe 
that the eventual translation of this technology will open 
new doors in the clinical setting. Phosphoproteomics, as 
an integrative approach with genomics and other omics 
data, may have a future hand in addressing the challenges 
of prostate cancer (and other cancer) diagnoses and drug 
development by identifying actionable pathways. The 
technology would also pave the way for a more compre-
hensive field of pharmaco-omics to rationally select and 
modify a patient’s drug therapy for different diseases that 
have low mutation burden.
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